-
Univariable associations between a history of incarceration and HIV and HCV prevalence among people who inject drugs across 17 countries in Europe 2006 to 2020 – is the precautionary principle applicable?
- Lucas Wiessing1 , Eleni Kalamara1,2 , Jack Stone3 , Peyman Altan4 , Luk Van Baelen5 , Anastasios Fotiou6 , D’Jamila Garcia1,7 , Joao Goulao8 , Bruno Guarita1 , Vivian Hope9 , Marie Jauffret-Roustide10,11,12,13 , Lina Jurgelaitienė14,15 , Martin Kåberg16,17 , Adeeba Kamarulzaman18 , Liis Lemsalu19 , Anda Kivite-Urtane20 , Branko Kolarić21,22 , Linda Montanari1 , Magdalena Rosińska23 , Lavinius Sava24 , Ilonka Horváth25 , Thomas Seyler1 , Vana Sypsa26 , Anna Tarján27 , Ioanna Yiasemi28 , Ruth Zimmermann29 , Marica Ferri1 , Kate Dolan30 , Anneli Uusküla31 , Peter Vickerman3
-
View Affiliations Hide AffiliationsAffiliations: 1 European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Public Health Unit, Lisbon, Portugal 2 EASO MTC Block A, Winemakers Wharf, Grand Harbour Valletta, Malta 3 Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom 4 Ministry of Health, Public Health General Directorate, Ankara, Turkey 5 Sciensano, Epidemiology and public health, Lifestyle and chronic diseases, Brussels, Belgium 6 University Mental Health, Neurosciences, & Precision Medicine Research Institute, Athens, Greece 7 NOVA FCSH – Universidade Nova de Lisboa, Lisbon, Portugal 8 General Director on Addictive Behaviours and Dependencies, Ministry of Health, Lisbon, Portugal 9 Public Health Institute, Liverpool John Moores University, Liverpool, United Kingdom 10 Centre d’Étude des Mouvements Sociaux (Inserm U1276/CNRS UMR8044/EHESS), Paris, France 11 Santé Publique France, Saint-Maurice, France 12 Baldy Center for Law and Social Policy, Buffalo University of Social Sciences, New York, United States 13 British Columbia Centre on Substance Use (BCCSU), Vancouver, Canada 14 Drug, Tobacco and Alcohol Control Department, Vilnius, Lithuania 15 Social Innovations and Science Centre, Vilnius, Lithuania 16 Stockholm Needle Exchange, Stockholm Centre for Dependency Disorders, Stockholm, Sweden 17 Department of Medicine Huddinge, Division of Infection and Dermatology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden 18 Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia 19 Centre for Prevention of Drug Addiction and Infectious Diseases, National Institute for Health Development, Tallinn, Estonia 20 Riga Stradins University, Institute of Public Health, Riga, Latvia 21 Andrija Stampar Teaching Institute of Public Health, Zagreb, Croatia 22 Medical Faculty, University of Rijeka, Rijeka, Croatia 23 National Institute of Public Health NIH – National Research Institute, Warsaw, Poland 24 National Antidrug Agency – Ministry of Internal Affairs, Bucharest, Romania 25 Gesundheit Österreich GmbH – Austrian National Public Health Institution, International Affairs and Consulting, Vienna, Austria 26 Department of Hygiene, Epidemiology and Medical Statistics, Medical School, National and Kapodistrian University of Athens, Athens, Greece 27 Hungarian Reitox National Focal Point, Budapest, Hungary 28 Monitoring Department, Cyprus National Addictions Authority, Nicosia, Cyprus 29 Robert Koch Institute, Department of Infectious Disease Epidemiology, Berlin, Germany 30 Program of International Research and Training, National Drug and Alcohol Research Centre, Sydney, Australia 31 Department of Family Medicine and Public Health, University of Tartu, Tartu, EstoniaLucas WiessingLucas.Wiessing emcdda.europa.eu
-
View Citation Hide Citation
Citation style for this article: Wiessing Lucas, Kalamara Eleni, Stone Jack, Altan Peyman, Van Baelen Luk, Fotiou Anastasios, Garcia D’Jamila, Goulao Joao, Guarita Bruno, Hope Vivian, Jauffret-Roustide Marie, Jurgelaitienė Lina , Kåberg Martin, Kamarulzaman Adeeba, Lemsalu Liis, Kivite-Urtane Anda, Kolarić Branko, Montanari Linda, Rosińska Magdalena, Sava Lavinius, Horváth Ilonka, Seyler Thomas, Sypsa Vana, Tarján Anna, Yiasemi Ioanna, Zimmermann Ruth, Ferri Marica, Dolan Kate, Uusküla Anneli, Vickerman Peter. Univariable associations between a history of incarceration and HIV and HCV prevalence among people who inject drugs across 17 countries in Europe 2006 to 2020 – is the precautionary principle applicable?. Euro Surveill. 2021;26(49):pii=2002093. https://doi.org/10.2807/1560-7917.ES.2021.26.49.2002093 Received: 14 Dec 2020; Accepted: 19 Aug 2021
Abstract
People who inject drugs (PWID) are frequently incarcerated, which is associated with multiple negative health outcomes.
We aimed to estimate the associations between a history of incarceration and prevalence of HIV and HCV infection among PWID in Europe.
Aggregate data from PWID recruited in drug services (excluding prison services) or elsewhere in the community were reported by 17 of 30 countries (16 per virus) collaborating in a European drug monitoring system (2006–2020; n = 52,368 HIV+/−; n = 47,268 HCV+/−). Country-specific odds ratios (OR) and prevalence ratios (PR) were calculated from country totals of HIV and HCV antibody status and self-reported life-time incarceration history, and pooled using meta-analyses. Country-specific and overall population attributable risk (PAR) were estimated using pooled PR.
Univariable HIV OR ranged between 0.73 and 6.37 (median: 2.1; pooled OR: 1.92; 95% CI: 1.52–2.42). Pooled PR was 1.66 (95% CI 1.38–1.98), giving a PAR of 25.8% (95% CI 16.7–34.0). Univariable anti-HCV OR ranged between 1.06 and 5.04 (median: 2.70; pooled OR: 2.51; 95% CI: 2.17–2.91). Pooled PR was 1.42 (95% CI: 1.28–1.58) and PAR 16.7% (95% CI: 11.8–21.7). Subgroup analyses showed differences in the OR for HCV by geographical region, with lower estimates in southern Europe.
In univariable analysis, a history of incarceration was associated with positive HIV and HCV serostatus among PWID in Europe. Applying the precautionary principle would suggest finding alternatives to incarceration of PWID and strengthening health and social services in prison and after release (‘throughcare’).
Article metrics loading...
Full text loading...
References
-
Dolan K, Khoei EM, Brentari C, Stevens A. Prisons and Drugs: A global review of incarceration, drug use and drug services. Oxford: The Beckley Foundation; 2007. Available from: https://www.beckleyfoundation.org/wp-content/uploads/2016/04/BF_Report_12.pdf
-
World Health Organization Regional Office for Europe (WHO/Europe). Prisons and health. Copenhagen: WHO/Europe; 2014. Available from: http://www.euro.who.int/__data/assets/pdf_file/0005/249188/Prisons-and-Health.pdf?ua=1
-
Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017;5(12):e1192-207. https://doi.org/10.1016/S2214-109X(17)30375-3 PMID: 29074409
-
Wood E, Werb D, Kazatchkine M, Kerr T, Hankins C, Gorna R, et al. Vienna Declaration: a call for evidence-based drug policies. Lancet. 2010;376(9738):310-2. https://doi.org/10.1016/S0140-6736(10)60958-0 PMID: 20650517
-
Sugarman OK, Bachhuber MA, Wennerstrom A, Bruno T, Springgate BF. Interventions for incarcerated adults with opioid use disorder in the United States: A systematic review with a focus on social determinants of health. PLoS One. 2020;15(1):e0227968. https://doi.org/10.1371/journal.pone.0227968 PMID: 31961908
-
Dolan K, Wirtz AL, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner SA, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016;388(10049):1089-102. https://doi.org/10.1016/S0140-6736(16)30466-4 PMID: 27427453
-
Stone J, Fraser H, Lim AG, Walker JG, Ward Z, MacGregor L, et al. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2018;18(12):1397-409. https://doi.org/10.1016/S1473-3099(18)30469-9 PMID: 30385157
-
Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, Hagan H, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology. 2013;58(4):1215-24. https://doi.org/10.1002/hep.26387 PMID: 23504650
-
Wirtz AL, Yeh PT, Flath NL, Beyrer C, Dolan K. HIV and viral hepatitis among imprisoned key populations. Epidemiol Rev. 2018;40(1):12-26. https://doi.org/10.1093/epirev/mxy003 PMID: 29688317
-
Zlodre J, Fazel S. All-cause and external mortality in released prisoners: systematic review and meta-analysis. Am J Public Health. 2012;102(12):e67-75. https://doi.org/10.2105/AJPH.2012.300764 PMID: 23078476
-
Merrall EL, Kariminia A, Binswanger IA, Hobbs MS, Farrell M, Marsden J, et al. Meta-analysis of drug-related deaths soon after release from prison. Addiction. 2010;105(9):1545-54. https://doi.org/10.1111/j.1360-0443.2010.02990.x PMID: 20579009
-
Degenhardt L, Larney S, Kimber J, Gisev N, Farrell M, Dobbins T, et al. The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. Addiction. 2014;109(8):1306-17. https://doi.org/10.1111/add.12536 PMID: 24612249
-
Strathdee SA, West BS, Reed E, Moazen B, Azim T, Dolan K. Substance Use and HIV among female sex workers and female prisoners: risk environments and implications for prevention, treatment, and policies. J Acquir Immune Defic Syndr. 2015;69(Suppl 2):S110-7. https://doi.org/10.1097/QAI.0000000000000624 PMID: 25978477
-
Fuge TG, Tsourtos G, Miller ER. A systematic review and meta-analyses on initiation, adherence and outcomes of antiretroviral therapy in incarcerated people. PLoS One. 2020;15(5):e0233355. https://doi.org/10.1371/journal.pone.0233355 PMID: 32421754
-
Ickowicz S, Salleh NAM, Fairbairn N, Richardson L, Small W, Milloy MJ. criminal justice system involvement as a risk factor for detectable plasma hiv viral load in people who use illicit drugs: a longitudinal cohort study. AIDS Behav. 2019;23(9):2634-9. https://doi.org/10.1007/s10461-019-02547-z PMID: 31236749
-
Milloy MJ, Kerr T, Buxton J, Rhodes T, Guillemi S, Hogg R, et al. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis. 2011;203(9):1215-21. https://doi.org/10.1093/infdis/jir032 PMID: 21459814
-
Rich JD, Beckwith CG, Macmadu A, Marshall BDL, Brinkley-Rubinstein L, Amon JJ, et al. Clinical care of incarcerated people with HIV, viral hepatitis, or tuberculosis. Lancet. 2016;388(10049):1103-14. https://doi.org/10.1016/S0140-6736(16)30379-8 PMID: 27427452
-
Semaille C, Le Strat Y, Chiron E, Chemlal K, Valantin MA, Serre P, et al. Prevalence of human immunodeficiency virus and hepatitis C virus among French prison inmates in 2010: a challenge for public health policy. Euro Surveill. 2013;18(28):20524. https://doi.org/10.2807/1560-7917.ES2013.18.28.20524 PMID: 23870097
-
Cunningham EB, Hajarizadeh B, Bretana NA, Amin J, Betz-Stablein B, Dore GJ, et al. Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: The HITS-p study. J Viral Hepat. 2017;24(9):733-41. https://doi.org/10.1111/jvh.12701 PMID: 28256027
-
Danis K, Doherty L, McCartney M, McCarrol J, Kennedy H. Hepatitis and HIV in Northern Ireland prisons: a cross-sectional study. Euro Surveill. 2007;12(1):3. https://doi.org/10.2807/esm.12.01.00674-en PMID: 27938649
-
Milloy MJ, Buxton J, Wood E, Li K, Montaner JS, Kerr T. Elevated HIV risk behaviour among recently incarcerated injection drug users in a Canadian setting: a longitudinal analysis. BMC Public Health. 2009;9(1):156. https://doi.org/10.1186/1471-2458-9-156 PMID: 19473508
-
Werb D, Kerr T, Small W, Li K, Montaner J, Wood E. HIV risks associated with incarceration among injection drug users: implications for prison-based public health strategies. J Public Health (Oxf). 2008;30(2):126-32. https://doi.org/10.1093/pubmed/fdn021 PMID: 18387974
-
Altice FL, Azbel L, Stone J, Brooks-Pollock E, Smyrnov P, Dvoriak S, et al. The perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. Lancet. 2016;388(10050):1228-48. https://doi.org/10.1016/S0140-6736(16)30856-X PMID: 27427455
-
Stone J, Martin NK, Hickman M, Hutchinson SJ, Aspinall E, Taylor A, et al. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction. 2017;112(7):1302-14. https://doi.org/10.1111/add.13783 PMID: 28257600
-
Treloar C, McCredie L, Lloyd AR. The Prison Economy of Needles and Syringes: What Opportunities Exist for Blood Borne Virus Risk Reduction When Prices Are so High? PLoS One. 2016;11(9):e0162399. PMID: 27611849
-
Wood E, Li K, Small W, Montaner JS, Schechter MT, Kerr T. Recent incarceration independently associated with syringe sharing by injection drug users. Public Health Rep. 2005;120(2):150-6. https://doi.org/10.1177/003335490512000208 PMID: 15842116
-
Michel L, Trouiller P, Chollet A, Molinier M, Duchesne L, Jauffret-Roustide M, ANRS-Coquelicot Study Group. Self-reported injection practices among people who use drugs in French prisons: Public health implications (ANRS-Coquelicot survey 2011-2013). Drug Alcohol Rev. 2018;37(Suppl 1):S268-76. https://doi.org/10.1111/dar.12620 PMID: 29105203
-
Cepeda JA, Niccolai LM, Lyubimova A, Kershaw T, Levina O, Heimer R. High-risk behaviors after release from incarceration among people who inject drugs in St. Petersburg, Russia. Drug Alcohol Depend. 2015;147:196-202. https://doi.org/10.1016/j.drugalcdep.2014.11.021 PMID: 25496706
-
Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, et al. Release from prison--a high risk of death for former inmates. N Engl J Med. 2007;356(2):157-65. https://doi.org/10.1056/NEJMsa064115 PMID: 17215533
-
Kariminia A, Law MG, Butler TG, Corben SP, Levy MH, Kaldor JM, et al. Factors associated with mortality in a cohort of Australian prisoners. Eur J Epidemiol. 2007;22(7):417-28. https://doi.org/10.1007/s10654-007-9134-1 PMID: 17668280
-
Merrall EL, Kariminia A, Binswanger IA, Hobbs MS, Farrell M, Marsden J, et al. Meta-analysis of drug-related deaths soon after release from prison. Addiction. 2010;105(9):1545-54. https://doi.org/10.1111/j.1360-0443.2010.02990.x PMID: 20579009
-
Borquez A, Beletsky L, Nosyk B, Strathdee SA, Madrazo A, Abramovitz D, et al. The effect of public health-oriented drug law reform on HIV incidence in people who inject drugs in Tijuana, Mexico: an epidemic modelling study. Lancet Public Health. 2018;3(9):e429-37. https://doi.org/10.1016/S2468-2667(18)30097-5 PMID: 30122559
-
Gassowski M, Nielsen S, Bannert N, Bock CT, Bremer V, Ross RS, et al. History of detention and the risk of hepatitis C among people who inject drugs in Germany. Int J Infect Dis. 2019;81:100-6. https://doi.org/10.1016/j.ijid.2019.01.015 PMID: 30658167
-
Michel L, Lions C, Van Malderen S, Schiltz J, Vanderplasschen W, Holm K, et al. Insufficient access to harm reduction measures in prisons in 5 countries (PRIDE Europe): a shared European public health concern. BMC Public Health. 2015;15(1):1093. https://doi.org/10.1186/s12889-015-2421-y PMID: 26507505
-
Stöver H, Hariga F. Prison-based needle and syringe programmes (PNSP) – Still highly controversial after all these years. Drugs Educ Prev Policy. 2016;23(2):103-12. https://doi.org/10.3109/09687637.2016.1148117
-
Kamarulzaman A, Reid SE, Schwitters A, Wiessing L, El-Bassel N, Dolan K, et al. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. Lancet. 2016;388(10049):1115-26. https://doi.org/10.1016/S0140-6736(16)30769-3 PMID: 27427456
-
Tarján A, Horváth G, Stöver H. European mapping of harm reduction interventions in prisons – revised version: July 2019. Frankfurt: Frankfurt University of Applied Sciences; 2019. Available from: https://www.researchgate.net/publication/335022280_European_Mapping_of_harm_reduction_interventions_in_prisons_-_Revised_version_July_2019
-
Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010;376(9738):355-66. https://doi.org/10.1016/S0140-6736(10)60832-X PMID: 20650513
-
MacDonald M, Williams J, Kane D. Barriers to implementing throughcare for problematic drug users in European prisons. Int J Prison Health. 2012;8(2):68-84. https://doi.org/10.1108/17449201211277192 PMID: 25758018
-
Stöver H, Jamin D, Sys O, Vanderplasschen W, Jauffret-Roustide M, Michel L, et al. Continuity of care for drug users in prisons and beyond in four European countries - Final report. Frankfurt: Frankfurt University of Applied Sciences; 2019. Available from: https://www.frankfurt-university.de/fileadmin/standard/Hochschule/Fachbereich_4/Forschung/ISFF/Forschungsprojekte/Abgeschlossene_Projekte/48h_out_finalreport_WP3_march2019.pdf
-
Friedman SR, Cooper HL, Tempalski B, Keem M, Friedman R, Flom PL, et al. Relationships of deterrence and law enforcement to drug-related harms among drug injectors in US metropolitan areas. AIDS. 2006;20(1):93-9. https://doi.org/10.1097/01.aids.0000196176.65551.a3 PMID: 16327324
-
Strathdee SA, Hallett TB, Bobrova N, Rhodes T, Booth R, Abdool R, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet. 2010;376(9737):268-84. https://doi.org/10.1016/S0140-6736(10)60743-X PMID: 20650523
-
Csete J, Kamarulzaman A, Kazatchkine M, Altice F, Balicki M, Buxton J, et al. Public health and international drug policy. Lancet. 2016;387(10026):1427-80. https://doi.org/10.1016/S0140-6736(16)00619-X PMID: 27021149
-
Strathdee SA, Beletsky L, Kerr T. HIV, drugs and the legal environment. Int J Drug Policy. 2015;26(Suppl 1):S27-32. https://doi.org/10.1016/j.drugpo.2014.09.001 PMID: 25265900
-
Hurley R. How to save drug users’ lives. BMJ. 2019;366:l5050. https://doi.org/10.1136/bmj.l5050 PMID: 21868460
-
Kruithof K, Davies M, Disley E, Strang L, Ito K. Study on alternatives to coercive sanctions as response to drug law offences and drug-related crimes. Brussels: European Commission; 2016. Available from: http://sisco.copolad.eu/web/uploads/documentos/PB_DGHOME_Publicacion_alternativas_encarcelamiento.pdf
-
Gjersing L. Decriminalisation and possible impact on prison population and drug related problems. Session on Prison and drugs in Europe. Lisbon Addiction conference 2019; 23-25 October 2019, Lisbon, Portugal. Available from: https://www.lisbonaddictions.eu/lisbon-addictions-2019/presentations/decriminalisation-and-possible-impact-prison-population-and-drug-related-problems
-
Hughes CE, Stevens A. The effects of the decriminalization of drug use in Portugal. Discussion paper. Oxford: The Beckley Foundation; 2007. Available from: https://kar.kent.ac.uk/13325/1/BFDPP_BP_14_EffectsOfDecriminalisation_EN.pdf.pdf
-
Gonçalves R, Lourenço A, Silva SN. A social cost perspective in the wake of the Portuguese strategy for the fight against drugs. Int J Drug Policy. 2015;26(2):199-209. https://doi.org/10.1016/j.drugpo.2014.08.017 PMID: 25265899
-
Tamhane AR, Westfall AO, Burkholder GA, Cutter GR. Prevalence odds ratio versus prevalence ratio: choice comes with consequences. Stat Med. 2016;35(30):5730-5. https://doi.org/10.1002/sim.7059 PMID: 27460748
-
United Nations Statistics Division. Methodology - Standard country or area codes for statistical use (M49). New York: United Nations. [Accessed: 15 Aug 2020]. Available from: https://unstats.un.org/unsd/methodology/m49
-
Institute for Crime & Justice Policy Research (ICPR). World prison brief. London: ICPR; 2020 [Accessed: 15 Aug 2020]. Available from: https://prisonstudies.org/world-prison-brief-data
-
Dolan K, Kite B, Black E, Aceijas C, Stimson GV, Reference Group on HIV/AIDS Prevention and Care among Injecting Drug Users in Developing and Transitional Countries. HIV in prison in low-income and middle-income countries. Lancet Infect Dis. 2007;7(1):32-41. https://doi.org/10.1016/S1473-3099(06)70685-5 PMID: 17182342
-
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Lithuania country drug report 2019. Lisbon: EMCDDA; 2019. Available from: https://www.emcdda.europa.eu/system/files/publications/11341/lithuania-cdr-2019_0.pdf
-
Kivimets K, Uusküla A, Lazarus JV, Ott K. Hepatitis C seropositivity among newly incarcerated prisoners in Estonia: data analysis of electronic health records from 2014 to 2015. BMC Infect Dis. 2018;18(1):339. https://doi.org/10.1186/s12879-018-3242-2 PMID: 30031373
-
Niculescu I, Paraschiv S, Paraskevis D, Abagiu A, Batan I, Banica L, et al. Recent HIV-1 outbreak among intravenous drug users in Romania: evidence for cocirculation of CRF14_BG and subtype F1 strains. AIDS Res Hum Retroviruses. 2015;31(5):488-95. https://doi.org/10.1089/aid.2014.0189 PMID: 25369079
-
McAuley A, Palmateer NE, Goldberg DJ, Trayner KMA, Shepherd SJ, Gunson RN, et al. Re-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis. Lancet HIV. 2019;6(5):e315-24. https://doi.org/10.1016/S2352-3018(19)30036-0 PMID: 30981674
-
Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol. 2008;168(10):1099-109. https://doi.org/10.1093/aje/kwn237 PMID: 18849303
-
Maher L, Chant K, Jalaludin B, Sargent P. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia. J Gastroenterol Hepatol. 2004;19(10):1114-20. https://doi.org/10.1111/j.1440-1746.2004.03438.x PMID: 15377287
-
Tyndall MW, Currie S, Spittal P, Li K, Wood E, O’Shaughnessy MV, et al. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS. 2003;17(6):887-93. https://doi.org/10.1097/00002030-200304110-00014 PMID: 12660536
-
Allen EJ, Palmateer NE, Hutchinson SJ, Cameron S, Goldberg DJ, Taylor A. Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland. Int J Drug Policy. 2012;23(5):346-52. https://doi.org/10.1016/j.drugpo.2012.07.006 PMID: 22940142
-
Sypsa V, Psichogiou M, Paraskevis D, Nikolopoulos G, Tsiara C, Paraskeva D, et al. Rapid decline in hiv incidence among persons who inject drugs during a fast-track combination prevention program after an hiv outbreak in Athens. J Infect Dis. 2017;215(10):1496-505. PMID: 28407106
-
Cullen KJ, Hope VD, Croxford S, Shute J, Ncube F, Parry JV. Factors associated with recently acquired hepatitis C virus infection in people who inject drugs in England, Wales and Northern Ireland: new findings from an unlinked anonymous monitoring survey. Epidemiol Infect. 2015;143(7):1398-407. https://doi.org/10.1017/S0950268814002040 PMID: 25119383
-
Memedovic S, Iversen J, Geddes L, Maher L. Australian NSP Survey. National Data Report 2012-2016. Prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees. National Data Report 2012-2016. Sydney: Kirby Institute; 2017. Available from: https://kirby.unsw.edu.au/sites/default/files/kirby/report/ANSPS_National-Data-Report-2012-2016.pdf
-
Fotiou A, Kanavou E, Antaraki A, Richardson C, Terzidou M, Kokkevi A, Drug Related Infectious Diseases (DRID) Medical Doctors Group of OKANA. HCV/HIV coinfection among people who inject drugs and enter opioid substitution treatment in Greece: prevalence and correlates. Hepatol Med Policy. 2016;1(1):9. https://doi.org/10.1186/s41124-016-0017-5 PMID: 30288313
-
Hatzakis A, Sypsa V, Paraskevis D, Nikolopoulos G, Tsiara C, Micha K, et al. Design and baseline findings of a large-scale rapid response to an HIV outbreak in people who inject drugs in Athens, Greece: the ARISTOTLE programme. Addiction. 2015;110(9):1453-67. https://doi.org/10.1111/add.12999 PMID: 26032121
-
Folch C, Casabona J, Espelt A, Majó X, Meroño M, Gonzalez V, et al. High Prevalence and Incidence of HIV and HCV Among New Injecting Drug Users With a Large Proportion of Migrants--Is Prevention Failing? Subst Use Misuse. 2016;51(2):250-60. https://doi.org/10.3109/10826084.2015.1092991 PMID: 26820260
-
Christensen PB, Krarup HB, Niesters HG, Norder H, Georgsen J. Prevalence and incidence of bloodborne viral infections among Danish prisoners. Eur J Epidemiol. 2000;16(11):1043-9. https://doi.org/10.1023/a:1010833917242 PMID: 11421474
-
Wiessing L. Epidemiology of HIV and viral hepatitis among people who inject drugs in Europe. Doctoral dissertation. Porto: University of Porto; 2017. Available from: https://repositorio-aberto.up.pt/bitstream/10216/110774/2/252084.docx
-
Aebi MF, Tiago MM. Prisons and prisoners in Europe 2019: key findings of the SPACE I report. Strasbourg, Lausanne: Council of Europe, Universite de Lausanne; 2020. Available from: http://wp.unil.ch/space/files/2020/04/Key-Findings-2019_200406.pdf
-
Tresó B, Barcsay E, Tarján A, Horváth G, Dencs A, Hettmann A, et al. Prevalence and correlates of HCV, HVB, and HIV infection among prison inmates and staff, Hungary. J Urban Health. 2012;89(1):108-16. https://doi.org/10.1007/s11524-011-9626-x PMID: 22143408
-
Unlu A, Tammi T, Hakkarainen P. Drug decriminalization policy literature review: models, implementation and outcomes. Report number: 9/2020. Helsinki: National Institute for Health and Welfare; 2020. Available from: https://www.researchgate.net/publication/342131913_Drug_Decriminalization_Policy_Literature_Review_Models_Implementation_and_Outcomes
-
Stevens A, Hughes CE, Hulme S, Cassidy R. Depenalization, diversion and decriminalization: A realist review and programme theory of alternatives to criminalization for simple drug possession. Eur J Criminol. 2019;0(0):1477370819887514. https://doi.org/10.1177/1477370819887514
-
Akiyama MJ, Spaulding AC, Rich JD. Flattening the curve for incarcerated populations - Covid-19 in jails and prisons. N Engl J Med. 2020;382(22):2075-7. https://doi.org/10.1056/NEJMp2005687 PMID: 32240582
-
Simpson PL, Butler TG. Covid-19, prison crowding, and release policies. BMJ. 2020;369:m1551. https://doi.org/10.1136/bmj.m1551 PMID: 32312733
-
Aebi MF, Tiago MM. Prisons and prisoners in Europe in pandemic times: an evaluation of the short-term impact of the COVID-19 on prison populations. Strasbourg, Lausanne: Council of Europe, Universite de Lausanne; 2020. Available from: http://wp.unil.ch/space/files/2020/06/Prisons-and-the-COVID-19_200617_FINAL.pdf
-
Chaudry RV. The Precautionary Principle, public health, and public health nursing. Public Health Nurs. 2008;25(3):261-8. https://doi.org/10.1111/j.1525-1446.2008.00703.x PMID: 18477377
-
Fischer AJ, Ghelardi G. The precautionary principle, evidence-based medicine, and decision theory in public health evaluation. Front Public Health. 2016;4:107. https://doi.org/10.3389/fpubh.2016.00107 PMID: 27458575
-
Wilson DP, Donald B, Shattock AJ, Wilson D, Fraser-Hurt N. The cost-effectiveness of harm reduction. Int J Drug Policy. 2015;26(Suppl 1):S5-11. https://doi.org/10.1016/j.drugpo.2014.11.007 PMID: 25727260
Data & Media loading...
Supplementary data
-
-
Supplement
-